Hospira Presents Updates on Biosimilar Inflectra for IBD at 2015 ECCO-IBD Conference

Hospira Presents Updates on Biosimilar Inflectra for IBD at 2015 ECCO-IBD Conference
hospiraRecently, IBD News Today reported on how Hospira, Inc. announced the launch of Inflectra (infliximab), the first biosimilar monoclonal antibody (mAb), in major European markets. Now, the company has been invited to the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference to present the latest research updates on the usage of Inflectra. The results show that patients treated with Inflectra have a comparable response to those treated with reference drug Remicade® (infliximab) to address both Crohn's disease and ulcerative colitis. The data presented supports Inflectra's indication as an inflammatory bowel disease (IBD) treatment. The results are based on an ongoing
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *